Article
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2018
Kang Jin, Chen Hua-Jun, Wang Zheng, Liu Jing, Li Bing, Zhang Tengfei, Yang Zhenfan, Wu Yi-Long, Yang Jin-Ji
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.